CD274 and neoplasm: In conclusion, we suggest, in addition to standardization of immunohistochemical (IHC) protocols for the detection of PD-L1 in tumor cells and tumor microenvironments of different cancer subtypes with a definition of adequate cut-offs, to also evaluate its expression in the whole section, to correctly define the real prognostic and predictive value of this marker in tumor disease.